Search
forLearn
5 / 801 resultslearn TDM-105795
learn oligopeptide-71
learn PTD-DBM
learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Research
5 / 931 resultsresearch Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231
Glibenclamide slows breast cancer cell growth by stopping cell division.
research In vitro anti-proliferative and antioxidant activites of chloroform extract of christia vespertilionis on mcf 7 and mda-mb-231 breast cancer cells
Christia vespertilionis extract may help fight breast cancer cells.
research Invasion and increased expression of S100A4 and CYR61 in mesenchymal transformed breast cancer cells is downregulated by GnRH
GnRH treatment can reduce breast cancer cell invasion.
research Anti-invasive effects of minoxidil on human breast cancer cells: combination with ranolazine
Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.
research Radyoterapinin Metastatik Meme Kanseri Hücrelerindeki Mitokondri İlişkili Yolaklar Üzerine Etkisi
Radiotherapy affects mitochondrial-related genes in metastatic breast cancer cells.
Community Join
5 / 1000+ resultscommunity Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community Went from almost balding to some this!
A user successfully regrew hair after nearly going bald by using oral finasteride, topical minoxidil, plasma injections, and mesotherapy over 9 months. They plan to try derma rolling and have an alarm set for taking medication, noting increased sexual drive as a side effect.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community Whats the deal with TDM-105795?
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.